Ractigen Therapeutics Announces Landmark Publication in Nature Medicine Highlighting Unprecedented Preclinical Efficacy and Positive First-in-Human Clinical Data for RAG-17 in SOD1-ALS

Data ReadoutpositiveRAG-17Positive

AI Analysis

Summary

Ractigen Therapeutics announced a landmark Nature Medicine publication highlighting positive first-in-human clinical data and preclinical efficacy for RAG-17, an RNAi therapy for SOD1-ALS, which met primary safety endpoints with no serious adverse events. The publication validates the company's proprietary SCAD delivery platform for CNS-targeted therapies.

Clinical Trial Data

Phase

Phase_1

Primary Endpoint

Met

Outcome Details

First-in-Human trial met primary safety endpoints with no Serious Adverse Events (SAEs); peer-reviewed publication in Nature Medicine highlighting preclinical efficacy and positive clinical data

Importance:7/10

Sentiment:

0.85

RAG-17SOD1-ALSRNAiCNSSCAD platformFirst-in-HumanNature Medicinepreclinicalsafety

Related Companies

$SHWZ $TRAX

Read the original article

Published by PR Newswire Biotech on July 15, 2026 12:47 PM

Read Original